{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,25]],"date-time":"2026-05-25T07:06:24Z","timestamp":1779692784524,"version":"3.53.1"},"reference-count":129,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2026,2,11]],"date-time":"2026-02-11T00:00:00Z","timestamp":1770768000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"},{"start":{"date-parts":[[2026,2,11]],"date-time":"2026-02-11T00:00:00Z","timestamp":1770768000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"funder":[{"DOI":"10.13039\/100009619","name":"Japan Agency for Medical Research and Development","doi-asserted-by":"publisher","award":["22mk0101227h0001"],"award-info":[{"award-number":["22mk0101227h0001"]}],"id":[{"id":"10.13039\/100009619","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009619","name":"Japan Agency for Medical Research and Development","doi-asserted-by":"publisher","award":["23mk0101227h0002"],"award-info":[{"award-number":["23mk0101227h0002"]}],"id":[{"id":"10.13039\/100009619","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009619","name":"Japan Agency for Medical Research and Development","doi-asserted-by":"publisher","award":["24mk0101227h0003"],"award-info":[{"award-number":["24mk0101227h0003"]}],"id":[{"id":"10.13039\/100009619","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009619","name":"Japan Agency for Medical Research and Development","doi-asserted-by":"publisher","award":["JP22dk0307113"],"award-info":[{"award-number":["JP22dk0307113"]}],"id":[{"id":"10.13039\/100009619","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009619","name":"Japan Agency for Medical Research and Development","doi-asserted-by":"publisher","award":["JP23ak0101215"],"award-info":[{"award-number":["JP23ak0101215"]}],"id":[{"id":"10.13039\/100009619","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["21K07518"],"award-info":[{"award-number":["21K07518"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["25K10859"],"award-info":[{"award-number":["25K10859"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Neuropsychopharm Rep"],"published-print":{"date-parts":[[2026,3]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:p>The cross\u2010national differences in automobile driving precautions stated in psychotropic drug package inserts primarily reflect regulatory policies and insufficient evaluation method standardization until recent years, rather than intrinsic ethnic differences. In January 2025, the Ministry of Health, Labour and Welfare (MHLW) of Japan issued the Criteria for Determining the Effects of Psychotropic Drugs on Motor Vehicle Driving Performance. These criteria were published as an appendix to an earlier guideline for evaluating these effects published in December 2022. These guidelines and criteria, developed by the authors, provide methods for evaluating the effects of psychotropic drugs. However, these are not intended to assess the fitness of an individual patient to drive. The MHLW guideline and criteria recommend a tiered approach for assessing clinically meaningful driving impairment. Adverse events affecting alertness, such as drowsiness, caused by psychotropic drugs on driving performance are more frequent during the initial treatment stages and dose escalation. Therefore, evaluating the effects of psychotropic drugs on driving performance requires careful consideration of the persistence of clinically meaningful impairment. Additionally, understanding the magnitude and duration of such effects is crucial for selecting appropriate treatments and offering effective guidance to patients. The MHLW criteria categorize the effects of psychotropic drugs on driving performance into four levels based on their magnitude and duration. Furthermore, the MHLW criteria could help to determine which clinical trials are necessary to evaluate the persistence of clinically meaningful impairment. Namely, the MHLW criteria could be used to structure the substantial evidence needed for evaluating the effects on driving performance for approval applications and clinical implementation.<\/jats:p>","DOI":"10.1002\/npr2.70092","type":"journal-article","created":{"date-parts":[[2026,2,12]],"date-time":"2026-02-12T02:51:31Z","timestamp":1770864691000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Evaluating and Determining the Effects of Psychotropic Drugs on Motor Vehicle Driving Performance: Key Considerations of the Japanese Guideline and Criteria for Clinical Implementation of Evidence"],"prefix":"10.1002","volume":"46","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4491-4851","authenticated-orcid":false,"given":"Tetsuo","family":"Nakabayashi","sequence":"first","affiliation":[{"name":"Pharmaceuticals and Medical Devices Agency  Tokyo Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3868-3372","authenticated-orcid":false,"given":"Kunihiro","family":"Iwamoto","sequence":"additional","affiliation":[{"name":"Department of Psychiatry Graduate School of Medicine, Nagoya University  Nagoya Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-8729-8750","authenticated-orcid":false,"given":"Akiko","family":"Yamaguchi","sequence":"additional","affiliation":[{"name":"Department of Psychiatry Graduate School of Medicine, Nagoya University  Nagoya Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6785-5095","authenticated-orcid":false,"given":"Yuki","family":"Konishi","sequence":"additional","affiliation":[{"name":"Department of Psychiatry University of Occupational and Environmental Health  Fukuoka Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0704-1054","authenticated-orcid":false,"given":"Momoe","family":"Saji","sequence":"additional","affiliation":[{"name":"Department of Neuropsychiatry Aichi Medical University  Nagakute Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7637-5576","authenticated-orcid":false,"given":"Reiji","family":"Yoshimura","sequence":"additional","affiliation":[{"name":"Department of Psychiatry University of Occupational and Environmental Health  Fukuoka Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6611-5244","authenticated-orcid":false,"given":"Kousuke","family":"Kanemoto","sequence":"additional","affiliation":[{"name":"Department of Neuropsychiatry Aichi Medical University  Nagakute Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4930-0181","authenticated-orcid":false,"given":"Hirofumi","family":"Aoki","sequence":"additional","affiliation":[{"name":"Institute of Innovation for Future Society, Nagoya University  Nagoya Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-5702-9755","authenticated-orcid":false,"given":"Masahiko","family":"Ando","sequence":"additional","affiliation":[{"name":"Department of Advanced Medicine Nagoya University Hospital  Nagoya Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7360-4898","authenticated-orcid":false,"given":"Norio","family":"Ozaki","sequence":"additional","affiliation":[{"name":"Pathophysiology of Mental Disorders, Nagoya University Graduate School of Medicine  Nagoya Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2026,2,11]]},"reference":[{"key":"e_1_2_14_2_1","doi-asserted-by":"publisher","DOI":"10.1017\/neu.2017.39"},{"key":"e_1_2_14_3_1","doi-asserted-by":"publisher","DOI":"10.1007\/164_2018_169"},{"key":"e_1_2_14_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbr.2021.113507"},{"key":"e_1_2_14_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(11)60602-8"},{"key":"e_1_2_14_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2215-0366(17)30015-9"},{"key":"e_1_2_14_7_1","doi-asserted-by":"publisher","DOI":"10.1093\/ijnp\/pyx056"},{"key":"e_1_2_14_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(98)04087-2"},{"key":"e_1_2_14_9_1","doi-asserted-by":"publisher","DOI":"10.1093\/ijnp\/pyz007"},{"key":"e_1_2_14_10_1","doi-asserted-by":"publisher","DOI":"10.1017\/S1461145713000552"},{"key":"e_1_2_14_11_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12888-025-07127-1"},{"key":"e_1_2_14_12_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41380-020-0843-0"},{"key":"e_1_2_14_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2215-0366(14)70314-1"},{"issue":"8","key":"e_1_2_14_14_1","article-title":"Maintenance Treatment With Antipsychotic Drugs for Schizophrenia","volume":"8","author":"Ceraso A.","year":"2020","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"e_1_2_14_15_1","doi-asserted-by":"publisher","DOI":"10.1093\/geront\/gnp127"},{"key":"e_1_2_14_16_1","doi-asserted-by":"publisher","DOI":"10.1503\/cmaj.250020"},{"key":"e_1_2_14_17_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.324.7346.1125"},{"key":"e_1_2_14_18_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.294.9.1025"},{"key":"e_1_2_14_19_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.279.14.1083"},{"key":"e_1_2_14_20_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.1995.03520410054026"},{"key":"e_1_2_14_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cpr.2004.07.008"},{"key":"e_1_2_14_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpsychires.2020.08.029"},{"key":"e_1_2_14_23_1","doi-asserted-by":"crossref","unstructured":"G. G.KayandB. K.Logan \u201cDrugged Driving Expert Panel Report: A Consensus Protocol for Assessing the Potential of Drugs to Impair Driving \u201d(2011) https:\/\/www.nhtsa.gov\/sites\/nhtsa.gov\/files\/811438.pdf.","DOI":"10.1037\/e729092011-001"},{"key":"e_1_2_14_24_1","doi-asserted-by":"publisher","DOI":"10.1080\/15389580490465201"},{"key":"e_1_2_14_25_1","unstructured":"Ministry of Health Labour and Welfare \u201cGuideline for Evaluating Psychotropic Drugs Effects on Driving Ability of Motor Vehicles [in Japanese]. PSEHB\/PED Notification No. 1227\u20103 and PSEHB\/PSD Notification No. 1227\u20101 \u201d(2022) https:\/\/www.pmda.go.jp\/files\/000250141.pdf."},{"key":"e_1_2_14_26_1","unstructured":"U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research (CDER) \u201cGuidance for Industry. Evaluating Drug Effects on the Ability to Operate a Motor Vehicle \u201d(2017) https:\/\/www.fda.gov\/regulatory\u2010information\/search\u2010fda\u2010guidance\u2010documents\/evaluating\u2010drug\u2010effects\u2010ability\u2010operate\u2010motor\u2010vehicle."},{"key":"e_1_2_14_27_1","doi-asserted-by":"publisher","DOI":"10.1002\/npr2.12339"},{"key":"e_1_2_14_28_1","doi-asserted-by":"publisher","DOI":"10.1002\/npr2.12436"},{"key":"e_1_2_14_29_1","unstructured":"Pharmaceuticals and Medical Devices Agency Office of New Drug III \u201cEARLY CONSIDERATION: Points to Consider for the Design of Clinical Trials to Assess the Effects of Psychotropic Drugs on Driving Performance \u201d(2024) https:\/\/www.pmda.go.jp\/files\/000271233.pdf."},{"key":"e_1_2_14_30_1","unstructured":"Ministry of Health Labour and Welfare \u201cAppendix to the Guideline for Evaluating Psychotropic Drugs Effects on Driving Ability of Motor Vehicles [in Japanese]. PSB\/PED Notification No. 0131\u20101 and PSB\/PSD Notification No. 0131\u20101 \u201d(2025) https:\/\/www.pmda.go.jp\/files\/000275374.pdf."},{"key":"e_1_2_14_31_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00213-013-3408-y"},{"key":"e_1_2_14_32_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.aap.2016.01.001"},{"key":"e_1_2_14_33_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00213-011-2484-0"},{"key":"e_1_2_14_34_1","doi-asserted-by":"publisher","DOI":"10.2147\/IJGM.S19639"},{"key":"e_1_2_14_35_1","volume-title":"Kaplan & Sadock's Comprehensive Textbook of Psychiatry, the Eleventh Edition (Kindle Edition)","author":"Ajilore O.","year":"2024"},{"issue":"2","key":"e_1_2_14_36_1","first-page":"161","article-title":"Is Behavioral Tolerance Learned?","volume":"21","author":"Vogel\u2010Sprott M.","year":"1997","journal-title":"Alcohol Health and Research World"},{"key":"e_1_2_14_37_1","doi-asserted-by":"publisher","DOI":"10.1055\/s-0043-113572"},{"key":"e_1_2_14_38_1","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.v64n0106"},{"key":"e_1_2_14_39_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.euroneuro.2024.01.011"},{"key":"e_1_2_14_40_1","doi-asserted-by":"publisher","DOI":"10.1002\/hup.2762"},{"key":"e_1_2_14_41_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.smrv.2012.05.004"},{"key":"e_1_2_14_42_1","unstructured":"Pharmaceuticals and Medical Devices Agency \u201cReport on the Investigation Results: Milnacipran Duloxetine and Venlafaxine \u201d(2016) https:\/\/www.pmda.go.jp\/files\/000215084.pdf."},{"key":"e_1_2_14_43_1","unstructured":"Pharmaceuticals and Medical Devices Agency \u201cReport of Investigation Results: Milnacipran Duloxetine and Venlafaxine [in Japanese] \u201d(2016) https:\/\/www.pmda.go.jp\/files\/000215087.pdf."},{"key":"e_1_2_14_44_1","doi-asserted-by":"publisher","DOI":"10.1097\/00004714-199806000-00006"},{"key":"e_1_2_14_45_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.euroneuro.2014.06.013"},{"key":"e_1_2_14_46_1","first-page":"555","article-title":"Double\u2010Blind, Comparative Study of Milnacipran and Paroxetine in Japanese Patients With Major Depression","volume":"9","author":"Kamijima K.","year":"2013","journal-title":"Neuropsychiatric Disease and Treatment"},{"key":"e_1_2_14_47_1","unstructured":"Shionogi Pharma Co. Ltd \u201cTrial No.: 16A203C (2.7.6.5.2) F1J\u2010US\u2010HMCR (a) (2.7.6.5.12) and F1J\u2010MC\u2010HMCQ (2.7.6.5.14). Common Technical Documents of Duloxetine Hydrochloride Posted on the Japanese Regulatory Agency [in Japanese] \u201d(2010) https:\/\/www.pmda.go.jp\/drugs\/2010\/P201000006\/index.html."},{"key":"e_1_2_14_48_1","doi-asserted-by":"publisher","DOI":"10.1185\/030079907X188107"},{"key":"e_1_2_14_49_1","doi-asserted-by":"publisher","DOI":"10.1111\/pcn.12648"},{"key":"e_1_2_14_50_1","doi-asserted-by":"publisher","DOI":"10.1111\/pcn.13332"},{"key":"e_1_2_14_51_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jad.2017.09.029"},{"issue":"14","key":"e_1_2_14_52_1","first-page":"2785","article-title":"Residual Effects of Zopiclone 7.5 mg on Highway Driving Performance in Insomnia Patients and Healthy Controls: A Placebo Controlled Crossover Study","volume":"231","author":"Leufkens T. R.","year":"2014","journal-title":"Psychopharmacology"},{"key":"e_1_2_14_53_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00213-017-4706-6"},{"key":"e_1_2_14_54_1","doi-asserted-by":"publisher","DOI":"10.1093\/ijnp\/pyab031"},{"key":"e_1_2_14_55_1","doi-asserted-by":"publisher","DOI":"10.1007\/978-3-7643-9923-8_3"},{"key":"e_1_2_14_56_1","doi-asserted-by":"publisher","DOI":"10.1111\/pcn.12734"},{"key":"e_1_2_14_57_1","volume-title":"Practice Guideline for the Treatment of Patients With Schizophrenia","author":"American Psychiatric Association","year":"2020"},{"key":"e_1_2_14_58_1","unstructured":"National Institute for Health and Care Excellence \u201cDepression in Adults: Treatment and Management (NG222) \u201d(2022) https:\/\/www.nice.org.uk\/guidance\/ng222\/resources\/depression\u2010in\u2010adults\u2010treatment\u2010and\u2010management\u2010pdf\u201066143832307909."},{"key":"e_1_2_14_59_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000005755"},{"key":"e_1_2_14_60_1","doi-asserted-by":"publisher","DOI":"10.5665\/SLEEP.1272"},{"key":"e_1_2_14_61_1","doi-asserted-by":"publisher","DOI":"10.5665\/sleep.5168"},{"key":"e_1_2_14_62_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00213-016-4375-x"},{"key":"e_1_2_14_63_1","doi-asserted-by":"publisher","DOI":"10.1093\/sleep\/zsy260"},{"key":"e_1_2_14_64_1","doi-asserted-by":"publisher","DOI":"10.1002\/hup.70007"},{"key":"e_1_2_14_65_1","doi-asserted-by":"publisher","DOI":"10.2174\/157488611798280933"},{"key":"e_1_2_14_66_1","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.v69n1205"},{"key":"e_1_2_14_67_1","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.2013.39"},{"key":"e_1_2_14_68_1","doi-asserted-by":"publisher","DOI":"10.1002\/hup.2327"},{"key":"e_1_2_14_69_1","doi-asserted-by":"publisher","DOI":"10.1002\/hup.2321"},{"key":"e_1_2_14_70_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.1984.tb02590.x"},{"key":"e_1_2_14_71_1","doi-asserted-by":"publisher","DOI":"10.1111\/cts.13145"},{"key":"e_1_2_14_72_1","doi-asserted-by":"publisher","DOI":"10.1111\/jsr.13430"},{"key":"e_1_2_14_73_1","doi-asserted-by":"publisher","DOI":"10.1177\/02698811221078764"},{"key":"e_1_2_14_74_1","doi-asserted-by":"publisher","DOI":"10.1111\/cts.70282"},{"key":"e_1_2_14_75_1","doi-asserted-by":"publisher","DOI":"10.1002\/cpt.2592"},{"key":"e_1_2_14_76_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00213-024-06687-6"},{"key":"e_1_2_14_77_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0001-4575(02)00134-3"},{"key":"e_1_2_14_78_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jsr.2008.02.030"},{"key":"e_1_2_14_79_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jsr.2009.07.002"},{"key":"e_1_2_14_80_1","first-page":"183","volume-title":"Alcohol Drugs Traffic Safety","author":"Louwerens J. W.","year":"1987"},{"key":"e_1_2_14_81_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00213-016-4519-z"},{"key":"e_1_2_14_82_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00213-020-05730-6"},{"key":"e_1_2_14_83_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.tips.2017.01.006"},{"key":"e_1_2_14_84_1","doi-asserted-by":"publisher","DOI":"10.1177\/0269881119836198"},{"key":"e_1_2_14_85_1","doi-asserted-by":"publisher","DOI":"10.1177\/2042098615579314"},{"key":"e_1_2_14_86_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.aap.2012.12.042"},{"key":"e_1_2_14_87_1","doi-asserted-by":"publisher","DOI":"10.3200\/GENP.133.4.329-335"},{"key":"e_1_2_14_88_1","doi-asserted-by":"publisher","DOI":"10.1038\/bjp.2008.30"},{"key":"e_1_2_14_89_1","doi-asserted-by":"publisher","DOI":"10.1093\/ijnp\/pyaa073"},{"key":"e_1_2_14_90_1","doi-asserted-by":"publisher","DOI":"10.1038\/srep44531"},{"key":"e_1_2_14_91_1","doi-asserted-by":"publisher","DOI":"10.2217\/pgs.11.68"},{"key":"e_1_2_14_92_1","doi-asserted-by":"publisher","DOI":"10.1093\/sleep\/zsaa032"},{"key":"e_1_2_14_93_1","doi-asserted-by":"publisher","DOI":"10.5664\/jcsm.6470"},{"key":"e_1_2_14_94_1","doi-asserted-by":"publisher","DOI":"10.1177\/0269881119855343"},{"key":"e_1_2_14_95_1","doi-asserted-by":"publisher","DOI":"10.1111\/jsr.14035"},{"key":"e_1_2_14_96_1","unstructured":"European Commission \u201cA Guideline on Summary of Product Characteristics (SmPC) Revision 2 \u201d(2009) https:\/\/health.ec.europa.eu\/document\/download\/6a043dea\u20107d0f\u20104252\u2010947b\u2010cef58f53d37e_en."},{"key":"e_1_2_14_97_1","unstructured":"T.G\u00f3mez\u2010Taleg\u00f3n I.Fierro M. C.Del R\u00edo andF. J.\u00c1lvarez \u201cEstablishment of Framework for Classification\/Categorisation and Labelling of Medicinal Drugs and Driving. Deliverable 4.3.1 DRUID (Driving Under the Influence of Drugs Alcohol and Medicines) 6th Framework Programme \u201d(2011)."},{"key":"e_1_2_14_98_1","unstructured":"H.Schulze M.Schumacher R.Urmeew et\u00a0al. \u201cDriving Under the Influence of Drugs Alcohol and Medicines in Europe\u2014Findings From the DRUID Project \u201d(2012)."},{"key":"e_1_2_14_99_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.2012.04279.x"},{"key":"e_1_2_14_100_1","doi-asserted-by":"crossref","unstructured":"H.Schulze M.Schumacher R.Urmeew et\u00a0al. \u201cFinal Report: Work Performed Main Results and Recommendations. Deliverable 0.1.8 DRUID (Driving Under the Influence of Drugs Alcohol and Medicines) 6th Framework Programme \u201d(2012).","DOI":"10.1093\/eurpub\/ckt126.151"},{"key":"e_1_2_14_101_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2024.52038"},{"key":"e_1_2_14_102_1","unstructured":"Taisho Pharmaceutical Co \u201cL. Vorzzz Tablets 2.5 mg\/Tablets 5 mg\/Tablets 10 mg. Package Insert [in Japanese] \u201d(2025) https:\/\/www.pmda.go.jp\/PmdaSearch\/iyakuDetail\/ResultDataSetPDF\/400059_1190034F1022_1_01."},{"key":"e_1_2_14_103_1","unstructured":"Taisho Pharmaceutical Co. Ltd. Trial No.: 207 (2.7.6.9) \u201cCommon Technical Documents of Duloxetine Hydrochloride Posted on the Japanese Regulatory Agency [in Japanese] \u201d(2024) https:\/\/www.pmda.go.jp\/drugs\/2025\/P20250902004\/index.html."},{"key":"e_1_2_14_104_1","unstructured":"Pharmaceuticals and Medical Devices Agency \u201cReview Report: Vorzzz Tablets 2.5 mg\/Tablets 5 mg\/Tablets 10 mg. [in Japanese] \u201d(2025) https:\/\/www.pmda.go.jp\/drugs\/2025\/P20250902004\/400059000_30700AMX00199_A100_1.pdf."},{"key":"e_1_2_14_105_1","doi-asserted-by":"publisher","DOI":"10.1002\/npr2.12469"},{"key":"e_1_2_14_106_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMcp2024526"},{"key":"e_1_2_14_107_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40263-021-00827-8"},{"key":"e_1_2_14_108_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2022.3880"},{"key":"e_1_2_14_109_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40263-023-01013-8"},{"key":"e_1_2_14_110_1","doi-asserted-by":"publisher","DOI":"10.1684\/j.1950-6945.2001.tb00392.x"},{"key":"e_1_2_14_111_1","doi-asserted-by":"publisher","DOI":"10.1586\/17512433.1.5.661"},{"key":"e_1_2_14_112_1","doi-asserted-by":"publisher","DOI":"10.1002\/pcn5.83"},{"key":"e_1_2_14_113_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.seizure.2021.09.003"},{"key":"e_1_2_14_114_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000005210"},{"key":"e_1_2_14_115_1","doi-asserted-by":"publisher","DOI":"10.1002\/jcph.10"},{"key":"e_1_2_14_116_1","doi-asserted-by":"publisher","DOI":"10.1111\/bcp.15481"},{"key":"e_1_2_14_117_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.seizure.2019.04.006"},{"key":"e_1_2_14_118_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1528-1157.1995.tb06007.x"},{"key":"e_1_2_14_119_1","unstructured":"Novartis Pharmaceuticals Corporation \u201cUS Label of Tegretol and Tegretol\u2010XR \u201d(2023) https:\/\/www.accessdata.fda.gov\/scripts\/cder\/daf\/index.cfm?event=overview.process&ApplNo=016608."},{"key":"e_1_2_14_120_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00213-010-1814-y"},{"key":"e_1_2_14_121_1","doi-asserted-by":"publisher","DOI":"10.1007\/s002130100898"},{"key":"e_1_2_14_122_1","unstructured":"U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research (CDER) Center for Biologics Evaluation and Research (CBER) and Oncology Center of Excellence (OCE) \u201cSubmitting Documents Using Real\u2010World Data and Real\u2010World Evidence to FDA for Drug and Biological Products Guidance for Industry \u201d(2022) https:\/\/www.fda.gov\/regulatory\u2010information\/search\u2010fda\u2010guidance\u2010documents\/submitting\u2010documents\u2010using\u2010real\u2010world\u2010data\u2010and\u2010real\u2010world\u2010evidence\u2010fda\u2010drug\u2010and\u2010biological\u2010products."},{"key":"e_1_2_14_123_1","doi-asserted-by":"publisher","DOI":"10.1002\/cpt.1413"},{"key":"e_1_2_14_124_1","doi-asserted-by":"publisher","DOI":"10.1002\/cpt.1633"},{"key":"e_1_2_14_125_1","doi-asserted-by":"publisher","DOI":"10.1186\/s40621-017-0107-x"},{"key":"e_1_2_14_126_1","doi-asserted-by":"publisher","DOI":"10.1055\/s-0043-111600"},{"key":"e_1_2_14_127_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jsr.2022.05.014"},{"key":"e_1_2_14_128_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000207464"},{"key":"e_1_2_14_129_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0236404"},{"key":"e_1_2_14_130_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eplepsyres.2018.08.011"}],"container-title":["Neuropsychopharmacology Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/npr2.70092","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/npr2.70092","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/npr2.70092","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,25]],"date-time":"2026-05-25T06:52:24Z","timestamp":1779691944000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/npr2.70092"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,11]]},"references-count":129,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,3]]}},"alternative-id":["10.1002\/npr2.70092"],"URL":"https:\/\/doi.org\/10.1002\/npr2.70092","archive":["Portico"],"relation":{},"ISSN":["2574-173X","2574-173X"],"issn-type":[{"value":"2574-173X","type":"print"},{"value":"2574-173X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,11]]},"assertion":[{"value":"2025-12-11","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-01-27","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-02-11","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e70092"}}